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Abstract
Background—Pseudomonas aeruginosa is an opportunistic pathogen problematic in causing
nosocomial infections and is highly susceptible to development of resistance to multiple
antibiotics. The gene encoding methionyl-tRNA synthetase (MetRS) from P. aeruginosa was
cloned and the resulting protein characterized.
Methods—MetRS was kinetically evaluated and the KM for its three substrates, methionine, ATP
and tRNAMet were determined to be 35, 515, and 29 μM, respectively. P. aeruginosa MetRS was
used to screen two chemical compound libraries containing 1690 individual compounds.
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Results—A natural product compound (BM01C11) was identified that inhibited the
aminoacylation function. The compound inhibited P. aeruginosa MetRS with an IC50 of 70 μM.
The minimum inhibitory concentration (MIC) of BM01C11 was determined against nine clinically
relevant bacterial strains, including efflux pump mutants and hypersensitive strains of P.
aeruginosa and E. coli. The MIC against the hypersensitive strain of P. aeruginosa was 16 μg/ml.
However, the compound was not effective against the wild-type and efflux pump mutant strains,
indicating that efflux may not be responsible for the lack of activity against the wild-type strains.
When tested in human cell cultures, the cytotoxicity concentration (CC50) was observed to be 30
μg/ml. The compound did not compete with methionine or ATP for binding MetRS, indicating that
the mechanism of action of the compound likely occurs outside the active site of aminoacylation.
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Conclusion—An inhibitor of P. aeruginosa MetRS, BM01C11, was identified as a flavonoid
compound named isopomiferin. Isopomiferin inhibited the enzymatic activity of MetRS and
displayed broad spectrum antibacterial activity. These studies indicate that isopomiferin may be
amenable to development as a therapeutic for bacterial infections.
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INTRODUCTION
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Antibiotic resistance is an issue of growing public concern. The rise of so-called ‘superbugs’
or bacteria that are resistant to multiple classes of antibiotics has marked the beginning of an
era where current antibiotic treatments are no longer sufficient [1]. Pseudomonas aeruginosa,
a Gram-negative pathogen, is a member of this group of bacteria and has a high intrinsic
resistance to antibiotics due to numerous efflux systems and low permeability of its
membrane. This bacterial pathogen is the leading cause of pulmonary infections in cystic
fibrosis patients and a significant contributor to hospital acquired infections [2].
Methionyl-tRNA synthetase (MetRS), encoded by the metS gene, binds three natural
substrates (ATP, methionine, and tRNA) and catalyzes the reaction resulting in the
aminoacylation of tRNAMet. MetRS is a class I aminoacyl tRNA synthetase (aaRS)
characterized by an active site structure formed by a Rossman fold containing two structural
motifs (HIGH and KMSKS) [3]. MetRS is further grouped along with isoleucyl-, valyl-,
leucyl-, cysteinyl- and arginyl-tRNA synthetases (IleRS, ValRS LeuRS, CysRS and ArgRS)
into a subclass Ia based on sequence conservation. A unique property of MetRS is its ability
to recognize and charge two tRNAMet substrates: the elongator tRNAMet and the initiator
tRNAMet. MetRS thus plays a crucial role during the initiation phase and the elongation
phase of protein biosynthesis.
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Most bacterial isolates contain one of the two major forms of MetRS (MetRS1 and MetRS2)
that are distinct at the amino acid sequence level and are encoded by two different genes,
metS1 and metS2, respectively. MetRS1 is the form typically found in Gram-positive
bacteria while MetRS2 appears to be the product of archaea and eukaryotic organisms as
well as the form found in Gram-negative bacteria [4]. There are exceptions to this in that
certain Gram-positive bacteria, in particular Streptococcus pneumoniae, contain genes
encoding both forms of MetRS, which is likely the result of acquisition through horizontal
gene transfer [5]. In addition, structural studies have divided MetRS into four additional
families based on the number of Zn-binding knuckle motifs and the number of Zn2+ atoms
bound to the motifs. MetRS2 contains two Zn-binding knuckles and either two Zn2+ (A
family) or one Zn2+ atom bound (B family). MetRS1 orthologs contain only one Zn-binding
knuckle motif and either one (C family) or no Zn2+ atoms bound (D family). Sequence
analysis indicates that MetRS from P. aeruginosa is of the MetRS2 form and belongs to the
B structural family based on Zn-binding knuckle motifs.
MetRS from P. aeruginosa was purified and the kinetic parameters (KM, Vmax and kcat) for
interaction with its natural substrates were experimentally determined. It was then developed
into a screening platform using scintillation proximity assay (SPA) technology [6] and used
to screen 1690 natural and synthetic compounds for inhibitory activity. One compound was
identified that inhibited the activity of the enzyme. This compound was further characterized
Curr Drug Discov Technol. Author manuscript; available in PMC 2018 January 29.
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for inhibition of enzymatic activity and bacterial growth, mode of action, mechanism of
inhibition and toxicity issues.

METHODS AND MATERIALS
Materials

Author Manuscript

All chemicals were obtained from Fisher Scientific (Pittsburg, PA). Radioactive isotopes,
SPA beads and 96-well screening plates were from PerkinElmer (Waltham, MA). E. coli
tolC mutant, P. aeruginosa PAO200 (efflux pump mutant) and P. aeruginosa hypersensitive
(ATCC® 35151™) strains were a kind gift from Urs Ochsner (Crestone Pharma, Boulder,
CO). All other bacteria were from American Type Culture Collection (ATCC) (Manassas,
VA). The synthetic compound library was from TimTec LLC (Newark, DE) and the natural
product library was from MicroSourceDiscovery Systems, Inc. (Gaylordsville, CT).
Compounds were supplied as 10 mM stocks dissolved in dimethyl sulfoxide (DMSO),
stored at −20 °C and thawed immediately before analysis. The compounds have an average
purity of 95%, and the minimum purity is at least 90%.
Cloning and Purification of P. aeruginosa MetRS
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The gene encoding P. aeruginosa MetRS was obtained through PCR amplification (MJ Mini
Thermo Cycler, Bio-Rad, Hercules, CA) using P. aeruginosa PAO1 (ATCC 47085) genomic
DNA as a substrate. A forward primer (5′ATATGCTAGCTCCGAACCACGCAAGATC-3′), designed to add an NheI restriction site
to the 5′ end of the gene and the reverse primer (5′CTCTAAGCTTTTACTTGACGCGCTGGC-3′) which was designed to add a HindIII
restriction site to the 3′ end of the gene, were used in the PCR. The PCR product was
inserted into a pET-28b(+) plasmid (Novagen) digested with NheI/HindIII. The recombinant
plasmid was transformed into E. coli Rosetta 2(DE3) Singles Competent Cells (EMD
Millipore, Danvers, MA).
The E. coli bacterial cultures were grown in Terrific Broth containing 25 μg/mL of
kanamycin and 50 μg/mL of chloramphenicol at a temperature of 37 °C to an optical density
(A600) of 0.6–0.8. The over-expression of P. aeruginosa MetRS in the cultures was induced
by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a concentration of 0.25
mM. Growth of the culture was continued for 2 hours post-induction, and cells were
harvested using centrifugation (10,000 g, 30 min, 4 °C). Fraction I lysates were prepared as
previously described [7]. P. aeruginosa MetRS was purified to more than 98% homogeneity
as previously described [6].
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Gel Electrophoresis and Protein Analysis
Proteins were visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) using 4–12% polyacrylamide precast gradient gels (Novex NuPAGE;
Invitrogen, Grand Island, NY) with 3-(N-morpholino) propanesulfonic acid (MOPS) as the
running buffer (Invitrogen). EZ-Run Rec Protein Ladder (Fisher Scientific) was used as a
protein standard. Coomassie Protein Assay Reagent (Thermo Scientific, Waltham, MA) was
used to determine protein concentrations with bovine serum albumin as a standard [8].
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Aminoacylation was measured using filter binding assays (50 μL) containing 50 mM TrisHCl (pH 7.5), 7.5 mM MgCl2, 2.5 mM ATP, 1 mM dithiothreitol (DTT), 75 μM [3H]
methionine, and 0.1 μM P. aeruginosa MetRS as previously described [9]. Assays were
stopped at time intervals between 1 and 5 min. The tRNA concentrations were varied in six
different sets of assays and contained 10, 30, 50, 70, 90 or 110 μM total tRNA (0.5, 1.5, 2.5,
3, 4, 5 μM tRNAMet). From the timed assays, initial velocities were measured and the kinetic
parameters (KM and kcat) were determined by fitting the data to the Michaelis-Menten
steady-state model using XLfit (IDBS).
Phosphate Exchange Reactions
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ATP:PPi exchange reactions (100 μl) were carried out at 37 ºC in 50.0 mM Tris-HCl (pH
7.5), 10 mM KF, 2 mM [32P]PPi, 7.5 mM MgCl2, 0.1 μM P. aeruginosa MetRS as previously
described [10]. The reactions were stopped at 1, 2, 3, 4, and 5 min intervals. In the reactions
in which the concentration of ATP was varied (25, 50, 100, 200, 300, and 400 μM), the
methionine concentration was held constant at 2 mM; alternatively, when the concentration
of the amino acid was varied (2.5, 5, 10, 20, 30 μM), the ATP concentration was at 2 mM.
Initial velocities were determined for exchange of PPi and the kinetic parameters (KM, Vmax
and Kcat) for the interactions of P. aeruginosa MetRS with ATP and methionine were
determined and fit to the Michaelis-Menten steady-state model using XLfit (IDBS).
Chemical Compound Screening
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In compound screening assays, the aminoacylation of tRNA was monitored using SPA
technology as previously described [10]. The reactions were carried out in 96-well microtiter
plates (Costar). Compounds were dissolved in 100% DMSO to a concentration of 3.3 mM,
and the final concentration of compounds in the screening assay was 132 μM. The
concentration of P. aeruginosa MetRS in the screening assays was set at 0.1 μM. To
determine IC50 values, the compounds were serially diluted into the assay at concentration
ranging from 200 μM down to 0.4 μM.
Microbiological Assays

Author Manuscript

Minimum inhibitory concentration (MIC) for the hit compound was obtained using broth
microdilutions following Clinical and Laboratory Safety Standards Institute (CLSI)
guideline M7-A7 [11]. MIC values were determined for E. coli (ATCC 25922), E. coli tolC
mutant, Enterococcus faecalis (ATCC 29212), Haemophilus influenzae (ATCC 49766), P.
aeruginosa (ATCC 47085), P. aeruginosa PAO200 (efflux pump mutant), P. aeruginosa
hypersensitive strain (ATCC 35151), Staphylococcus aureus (ATCC 29213), and
Streptococcus pneumonia (ATCC 49619). Quality control (QC) of MIC data and culture
purity was maintained by MIC determination for antibiotics specific for each bacterial strain
[10] as described in Table 1: Summary of Etest® Performance, Interpretive Criteria and
Quality Control Ranges (Biomerieux).
Time-kill studies were performed to determine mode of inhibition of the hit compound using
H. influenzae and S. aureus based on the MIC assay results, according to the CLSI
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document M26-A [12]. Growth media was Haemophilus Test Broth and Trypticase Soy
Broth from Remel (Lenexa, KS).
Cytotoxicity Testing
To determine the effect of the hit compound on the growth of human cell cultures, in vitro
cytotoxicity testing was carried out as described using human embryonic kidney 293 cells
(HEK-293) [6]. The Trevigen TACS® MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5Diphenyltetrazolium Bromide) Cell Proliferation Assay Kit (Gaithersburg, MD) was used to
analyze the impact of the hit compound on human cell proliferation and/or viability. The
control staurosporine was serially diluted in assays from 1 to 0.001 μg/ml and the hit
compound was tested in assays ranging from 100 μg/ml to 1 μg/ml.
Binding Mode Assay
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To determine the mechanism of action of the hit compound with respect to ATP and
methionine, IC50 values were determined using SPA assays as described above. Final
compound concentrations in each IC50 reaction ranged from 200 to 0.4 μM. Competition
with ATP was determined at 25, 50, 100, 250, 500, 1000 μM ATP while the methionine
concentration was 75 μM. Competition with the amino acid was determined at 25, 50, 100,
200, 300 μM methionine while the ATP concentration was 2.5 mM. Positive controls
contained only DMSO (2 μl) without compound.

RESULTS AND DISCUSSION
Sequence Analysis

Author Manuscript

The crystal structures of bacterial MetRS from E. coli [13, 14] and Thermus thermophilus
[15] and Brucella melitensis [16] in an apo-form and bound to its substrates have been
solved. Also the MetRS structure from the archaea Pyrococcus abyssi is known [17]. The
amino acid sequence of MetRS from P. aeruginosa exhibits a high degree of conservation
when compared with corresponding enzymes of the γ-subdivision of the proteobacteria
resulting in 73% sequence similarity and 61% sequence identity (Table 1). The level of
conservation is reduced considerably when compared with MetRS from other phyla and
when compared with either human mitochondrial MetRS (hmMetRS), or human cytosolic
MetRS (hcMetRS), there is only 18% conservation of the amino acid residues.

Author Manuscript

MetRS binds methionine (Met) through an induced-fit mechanism [14] and the active site
residues, Y15, W253 and H301 (E. coli numbering), that have been shown to directly
interact with the amino acid substrate are contained within the Rossmann fold in the
catalytic domain and are strictly conserved between E. coli, T. thermophilus and P.
aeruginosa MetRS (Fig. 1). These residues, along with others, make up the methionine
binding pocket of MetRS, in which the amino acid residues are conserved between E. coli
and P. aeruginosa MetRS, but greater variation occurs in the T. thermophilus enzyme.
MetRS must discriminate between the binding of methionine and homocysteine (a precursor
of cysteine). Two amino acids, L13 and Y260, that are located in the methionine binding
pocket form H-bonds with the δ-sulfur atom of methionine and, along with W253 and Y15,
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create the binding pocket surrounding the side-chain, resulting in specificity for methionine
[18][14]. L13 and Y260 are conserved in MetRS from E. coli and P. aeruginosa.
Binding of the ATP is stabilized by several residues. In E. coli MetRS, V326 and H23
appear to form H-bonds with the adenine base [14]. In both P. aeruginosa and T.
thermophilus, the valine at position 326 is replaced by the similar leucine. The ribose sugar
of ATP is stabilized by interactions with E27, G294, and D296. The amino acids at positions
294 and 296 are conserved in all three MetRS enzymes. However, the glutamic acid at
position 27 is replaced with a threonine in T. thermophilus MetRS. The two histidine
residues in the HLGH (HIGH) motif interact with the adenosine moiety of the ATP and H24
likely stabilizes the phosphate in the aminoacyladenylate [14]. These amino acids are also
strictly conserved in the three MetRS proteins.
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A number of amino acids have been shown to interact with and proofread the cognate tRNA
[13]. In sequence alignments (Fig. 1) these amino acids are fairly well conserved between
MetRS from E. coli, P. aeruginosa and T. thermophilus. At only one position, D456 (E. coli
numbering), is there a lack of conservation. The aspartic acid in E. coli is replaced with an
alanine and an asparagine in P. aeruginosa and T. thermophilus, respectively. This is
interesting since D456 in E. coli is one of two amino acid residues behaving as “antideterminants” contributing to rejection of non-methionine anticodon containing tRNAs [19].

Author Manuscript

MetRS is a known zinc metalloprotein, in which binding of Zn2+ is required for enzymatic
activity [20][21]. Sequence alignment of the amino acids from various MetRS proteins
identified four families in context of the number of zinc-binding ligands and the number of
Zn2+ bound [13]. E. coli contains four zinc-binding motifs (1–4), but only motif 2 and motif
3 actively bind Zn2+ (Fig. 1). Alternatively, T. thermophilus MetRS contains only two zincbinding motifs and binds one Zn2+ [15]. In the alignment in Fig. 1, MetRS from P.
aeruginosa aligns more closely with that of E. coli, containing all four of the zinc-binding
motifs, and with the lack of cysteine residues in motifs 1 and 3, like E. coli MetRS, likely
only binds one Zn2+ in what is considered the distal knuckle.
Expression and Characterization of MetRS from P. aeruginosa
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Methionyl-tRNA synthetase from P. aeruginosa was cloned, overexpressed in E. coli and
purified to greater than 98% homogeneity as visualized by SDS-PAGE and shown to be
active in the aminoacylation assay (Fig. 2A). The primary physiological function of an
aminoacyl tRNA synthetase (aaRS) is the catalytic attachment of an amino acid to its
cognate tRNA. This reaction occurs via two distinct enzymatic steps catalyzed without the
amino acid substrate being released from the enzyme. In the first step the enzyme catalyzes
the condensation of the amino acid and another substrate, ATP, forming an aminoacyl
adenylate intermediate with the release of an inorganic pyrophosphate (PPi). This reaction is
reversible in the absence of cognate tRNA and can be used to monitor the interaction of the
enzyme with the amino acid and ATP. The kinetic parameters governing the interaction of P.
aeruginosa MetRS with methionine and ATP were determined using the ATP:PPi exchange
reaction as described under the “Methods and Material” section. To determine the kinetic
parameters with respect to ATP, the amino acid concentration was held constant while ATP
concentrations were varied between 25 and 400 μM. Alternatively, to determine the kinetic
Curr Drug Discov Technol. Author manuscript; available in PMC 2018 January 29.
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parameters with respect to the amino acid, the ATP concentration was held constant while
the methionine concentrations were varied between 2.5 and 30 μM. The initial velocities
were determined and fit to the Michaelis-Menten steady-state model using XLfit (IDBS)
(Fig. 2B–C). The kinetic parameters, KM, kcat, and kcat/KM, for interaction of P. aeruginosa
MetRS with ATP were determined to be 515 μM, 24.2 sec−1, and 0.05 s−1μM−1, respectively
(Table 2). The same kinetic parameters for the interaction with methionine were 35 μM, 37.2
sec−1, and 1.1 s−1μM−1, also respectively. These values are similar to the kinetic interactions
previously observed for E. coli MetRS with ATP (KM = 528 μM, kcat = 74 μM) and
methionine (KM = 21 μM, kcat = 74 μM) [22].
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In the second step of the reaction the methionine is released from the aminoacyl adenylate
and transferred to the acceptor end of the cognate tRNAMet. This step tends to be the rate
limiting step and the turnover number for the entire aminoacylation reaction is well below
that for formation of the aminoacyl adenylate. In these reactions the concentration of Met
and ATP were saturating and the concentration of tRNAMet was varied between 0.5 and 5
μM. The initial velocities were determined and fit to the Michaelis-Menten steady-state
model (Fig. 2D) and the KM, kcat, and kcat/KM values for tRNA were determined to be 29.0
μM, 1.90 sec−1, and 0.07 s−1μM−1 respectively.
Chemical Compound Screening
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The chemical compound screening assays were based on the aminoacylation assay and
modified for monitoring using SPA technology. Initially, the non-enzymatic components of
the aminoacylation reaction were individually titrated into the assay to ensure optimal
concentrations for maximum signal. Next, MetRS was titrated into the assay to determine
the concentration yielding maximum sensitivity to enzymatic inhibition; this resulted in a
screening concentration of 0.1 μM (Fig. 2A). Using this optimized assay, two chemical
compound libraries were screened against the activity of P. aeruginosa MetRS. One library
contained 800 compounds composed of natural products including simple and complex
oxygen heterocycles, alkaloids, sesquiterpenes, diterpenes, pentacyclic triterpenes, and
sterols from Microsource Discovery Systems (Gaylordsville, CT) [9]. The other library
contained 890 low molecular weight synthetic compounds with scaffolds based on known
anti-bacterial, anti-fungoid, and anti-microbial agents from TimTec LLC (Newark, DE) [23].
The chemical compounds (3.3 mM) were dissolved in DMSO and screening reactions (50
μl) contained 2 μl of compound resulting in a final compound concentration of 132 μM. This
also resulted in 4% DMSO in each reaction. To determine the effect of DMSO on the
activity of MetRS, it was titrated into the assay up to 10% final concentration. There was no
decrease in enzymatic activity observed at 4% DMSO (data not shown). The screening
reactions were very robust with an average signal to background ratio of 10:1. The Z′ and Z
factors across all plates averaged 0.7 and 0.5, respectively. Screening assays were performed
as single point assays and compounds observed to inhibit at least 50% of enzymatic activity
were confirmed in additional assays performed in triplicate. The initial screen resulted in
eleven confirmed hit compounds. These compounds were analyzed to determine IC50 values.
Only two compounds, BM01C11 (70 μM) and BM01F04 (8.3 μM), both from the natural
compound library, were observed to have an IC50 value below 200 μM. BM01F04 was
identified as a compound named hieracin, also called Tricetin. The PubChem BioAssay
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database was searched for biological activity of hieracin and it was found to have inhibitory
activity against a number of eukaryotic and viral targets as well as antibacterial activity [24].
This compound will not be analyzed further. BM01C11 was identified as a compound
named isopomiferin (Fig. 3). The Pub-Chem BioAssay database was also searched for
biological activity of isopomiferin and a close conformer, isopomiferin dimethyl ether. There
was no inhibitory bioactivity found for this compound and it will be investigated further.
Microbiological Assays

Author Manuscript
Author Manuscript

Isopomiferin was tested in broth microdilution assays to determine minimum inhibitory
concentrations (MIC) against nine pathogenic bacteria (Table 3). The organisms used to
determine the MICs were chosen using Clinical Laboratory Standards Institute guidelines
[11] along with efflux and hypersensitive mutant strains of E. coli and P. aeruginosa. There
was no inhibition of wild-type E. coli or P. aeruginosa observed at concentrations below 128
μg/ml. There was also no inhibitory activity observed with the efflux pump mutant of P.
aeruginosa and only a slight decrease in the MIC with the efflux pump mutant of E. coli.
However, isopomiferin inhibited the growth of cultures of the hypersensitive strain of P.
aeruginosa with a moderately low MIC of 16 μg/ml, indicating that efflux may not be
responsible for the lack of activity against the wild-type strains. The hypersensitive strain of
P. aeruginosa is susceptible to numerous antibiotics because of an increase in outer
membrane permeability partially due to a malfunction in porin protein F [25]. Therefore, the
inability of isopomiferin to effect the growth of wild-type and efflux pump mutant strains of
P. aeruginosa may be a permeability issue. The other Gram-negative bacteria, Haemophilus
influenzae, does not contain a porin protein F and was susceptible to the compound.
Isopomifer-in inhibited growth of cultures of the Gram-positive bacteria, Enterococcus
faecalis and Staphylococcus aureus, but the compound did not inhibit the growth of
Streptococcus pneumoniae at a concentration lower than 128 μg/ml. This may be due to the
fact that S. pneumoniae contains two genes (metS1and metS2) encoding two distinctly
different forms of MetRS [4] and both forms of the protein may not be compromised by the
compound.
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Next, to determine the mode of inhibition in bacterial cultures, time kill studies were
performed with isopomiferin. Based on MIC results, isopomiferin was tested against
cultures of H. influenzae and S. aureus. The cultures were analyzed between 0 and 24 hours
and contained compounds at four times the MIC. H. influenzae grown in the presence of
isopomiferin was observed to have constant growth in the presence of compounds, but a
decrease of 2 to 5 log10 colony forming units (CFU) compared to the control during the
twenty-four hour period (Fig. 4). This is indicative of bacteriostatic inhibition and occurs, in
this case, because inhibition of aminoacylation by an amino-acyl tRNA synthetase produces
the same results as amino acid starvation, and likely activates the stringent response, which
results in static bacterial growth [26]. The effect of isopomiferin on cultures containing S.
aureus were observed to be bactericidal and no CFUs were observed in the first six hours of
growth. However, increased growth was observed at 24 hours, possibly because the
compounds lost potency over extended time periods. S. aureus contains MetRS1 and H.
influenzae contains MetRS2, and the different forms of the synthetase may contribute to the
difference observed in the mode of inhibition. The reason for the bactericidal activity is not
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clear, but many aaRS proteins have secondary roles that could be affected by the compound
leading to cell death. MetRS contains an editing function which prevents the
misaminoacylation of tRNAMet with homocysteine (Hcy). Blocking this editing function
could result in the incorporation of Hcy into nascent proteins, which in turn would inactivate
the biological activity of these proteins, possibly leading to cell death [27]. Alternatively,
inhibition of the editing function could result in the misaminoacylation of the initiator
tRNAMet, thus blocking initiation of protein synthesis.
Cytotoxicity Assays
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Mammalian cells contain a cytoplasmic as well as a mitochondrial form of MetRS, which
have many structural similarities with bacterial MetRS. This presents the potential that a
compound which is active in inhibition of bacterial MetRS may have cytotoxic effects on
eukaryotic cells. It was therefore important to analyze the potential for toxicity by
isopomiferin in eukaryotic cells. Predicting toxicity of chemicals using human cell systems
instead of whole animal systems is a viable first step in drug discovery, therefore
isopomiferin was tested for cytotoxicity in human embryonic kidney 293 (HEK-293) cell
cultures using the Trevigen TACS® MTT Cell Proliferation Assay Kit (Fig. 5).
Staurosporine, a potent inhibitor of human cell cultures [28], was used as a comparator in
the studies. Staurosporine was observed to inhibit cell growth with a CC50 of 0.003 μg/ml.
MTT assays were performed at isopomiferin concentrations between 1 and 100 μg/ml for 24
hours. Isopomiferin exhibited a CC50 of near 30 μg/ml, which when compared to the toxicity
of many antibiotics appears problematic for therapeutic use. However, the CC50 of
isopomiferin is 10,000-fold higher than that of staurosporine, and when compared with other
antibiotics, erythromycin and tetracycline, the toxicity profile was similar [29].

Author Manuscript

Mechanism of Action
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The binding sites of both ATP and methionine are located in the Rossman fold active site
region of MetRS. Small molecules primarily used in drug screening have a molecular mass
that is similar to both ATP and the amino acid. It is therefore prudent as an initial
determination of the mechanism of action to ascertain if a hit compound interferes with
binding of one or both of these substrates. An inhibitory compound that competes with ATP
for binding may be a poor candidate for drug development, since ATPase enzymes are
prevalent in both bacterial and eukaryotic cells. However, since methionine uniquely binds
MetRS in an induced fit mechanism, competitive inhibition of this mechanism could be very
specific. To understand the mechanism of action relative to substrate binding, isopomiferin
was tested in competition assays with varying amounts of ATP or methionine (Fig. 6). The
compound was not observed to compete with either ATP or methionine for binding,
indicating that the binding region of isopomiferin is likely outside the active site for
aminoacylation. In the assays, as the concentration of either ATP or methionine was
increased the IC50 remained constant, indicating a non-competitive form of inhibition [30].

CONCLUSION
The amino acid sequence of P. aeruginosa MetRS, when compared to homologs obtained
from a variety of bacterial species was, as expected, more similar (greater than 60%
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sequence conservation) to that of other MetRS proteins from the gamma subdivision of the
proteobacteria (Table 1). In particular, the critical amino acid residues in E. coli MetRS are
strictly conserved in P. aeruginosa MetRS. However, when compared with human cytosolic
or mitochondrial MetRS, there is little conservation of the primary sequence, indicating that
a compound that inhibits the function of the bacterial MetRS may be ineffective against the
human forms of MetRS. In the present work, P. aeruginosa MetRS was developed into a
screening platform based on scintillation proximity assay technology and used to screen two
chemical compound libraries (1690 compounds) for inhibitors of aminoacylation activity.
The screening assays were robust and eleven compounds from the compound libraries were
identified and confirmed as hit compounds. Two of the compounds, isopomiferin
(BM01C11) and hieracin (BM01F04), both natural products, inhibited MetRS activity with
IC50s of 70 μM and 8.3 μM, respectively. Hieracin was discarded due to promiscuous
inhibitory activity observed in bioassay data (National Center for Biotechnology
Information. PubChem Compound Database; CID=5281701, https://
pubchem.ncbi.nlm.nih.gov/compound/5281701 (accessed Feb. 9, 2017). Isopomiferin
displayed inhibition against bacterial growth from a panel of both Gram-negative and Grampositive bacteria. Moderate activity was observed against S. aureus, E. faecalis, and H.
influenzae. However, the wild-type and efflux pump mutant strains of E. coli and P.
aeruginosa were not affected by the compounds, indicating that the mechanism of resistance
may not be due to efflux. Cultures of the antibiotic hypersensitive strain of P. aeruginosa
were inhibited by isopomiferin. This suggest that the lack of inhibitory activity against the
wild-type and efflux pump mutant strains may be due to an inability to gain entry into the
cells.
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When isopomiferin was tested in human cell cultures, the CC50 was observed to be near 30
μg/ml. When compared with a small subset of antibiotics, this is not unusual. However,
when compared with the majority of antibiotics in use, this is a relatively high toxicity level.
The toxicity issue with isopomiferin will need to be addressed in future structure activity
relationship (SAR) studies. Isopomiferin did not interfere with MetRS binding of
methionine or with ATP, and would appear to inhibit the activity of MetRS by another
mechanism. It is possible that the compound may interact with the Zn++ binding motif
interfering with coordination of the metal due to the catechol moiety or it may bind at an
unknown site thereby inducing a conformational change in the protein leading to inactivation
of enzymatic function. In this era of multi-drug resistant bacteria, compounds that interact
with molecular targets differently, possibly with a different mechanism of action, or with
different binding sites, would be advantageous. This is evidenced by the low level of clinical
resistance observed, even after many years of use, against mupirocin that occurs by
mutations in the IleRS protein itself. Mupirocin blocks the binding site of the unique
aminoacyl adenylate intermediary molecule [31]. Higher levels of resistance come from the
acquisition of the mupA gene, normally from outside sources [32]. Also, the structure of
isopomiferin offers several avenues in which chemical modifications can be made in
attempts to increase potency against the growth of bacteria and to decrease toxicity observed
in human cell lines.
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Aminoacyl-tRNA synthetase
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3-(N-morpholino)propanesulfonic acid
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Structure-activity relationship

SPA

Scintillation proximity assay

TCA

Trichloroacetic acid
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Fig. 1.
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Sequence alignment of P. aeruginosa MetRS and close analogs. The protein sequences were
downloaded from the National Center for Biotechnology Information (NCBI). Abbreviations
are: Ec, E. coli; Pa, P. aeruginosa; Tth, T. thermophiles. Accession numbers for MetRS
protein sequences of E. coli, P. aeruginosa, and T. thermophiles are P00959, NP_252172 and
P23395, respectively. Sequence alignments were performed using Vector NTI Advance (TM)
11.0 (Invitrogen). Identical amino acid residues are white on black and similar residues are
black on grey. The positions of the HIGH and KMSKS motifs are indicated. Motifs 1–4
containing zinc binding knuckles in E. coli and P. aeruginosa are indicated above the motifs
using solid brackets and zinc binding knuckles in T. thermophilus are indicated below the
motifs using dashed brackets. Amino acid residues that directly interact with Met are
indicated with a cross (✖), and additional residues that form the amino acid binding pocket
are indicated with a bar (▬). Amino acids that directly interact with ATP (★) and tRNA (●)
are indicated. Amino acid residues that function in proofreading cognate tRNA are indicated
by open circles (○).
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Fig. 2.
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Determination of activity and the kinetic parameters governing the catalytic enzymology of
P. aeruginosa MetRS with the substrates tRNAMet, ATP, and methionine. (A) Titration of P.
aeruginosa MetRS into the aminoacylation assay to determine activity and the optimal
concentration in compound screening assays. Initial velocities for the interaction of P.
aeruginosa MetRS with (B) ATP, (C) methionine and (D) tRNAMet were determined and the
data were fit to a Michaelis-Menten steady-state model using XLfit (IDBS) to determine KM
and Vmax.
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Fig. 3.

The chemical structure of the hit compound BM01C11 (isopomiferin).
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Fig. 4.
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Time-kill kinetics of the hit compound isopomiferin against (A) H. influenzae and (B) S.
aureus. Isopomiferin was added to bacterial cultures at 4×MIC. Samples were analyzed by
plating and determination of colony forming units (CFU) at 0, 2, 4, 6, and 24 h. Filled
circles (●) represent control cultures containing no compound but an equal amount of
DMSO. Filled triangles (▲) represent cultures containing isopomiferin.
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Determination of the toxicity of isopomiferin in human cell cultures. MTT assays were
performed for 24 hours under standard tissue culture conditions as described in ‘Materials
and Methods’. The control (A) staurosporine was serially diluted in assays from 1 to 0.001
μg/ml to determine CC50 (0.003 μg/ml). Isopomiferin (B) was diluted in the assays from 100
to 1 μg/ml. The “% Positive” indicates the percent of activity observed relative to activity in
assays where only DMSO was added to the assay in the absence of compound. The data
points represents an average value of assays carried out in triplicate. The curve fits and CC50
values were determined using the Sigmoidal Dose-Response Model in XLfit 5.3 (IDBS).
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Determination of the mechanism of action of isopomiferin relative to (A) ATP and (B)
methionine. IC50s were determined in the aminoacylation assay using the SPA format. To
determine isopomiferin inhibition relative to ATP, the IC50s were determined at six different
ATP concentrations ranging from 25 to 1000 μM. To determine inhibition relative to
methionine, the IC50s were determined at five different methionine concentrations ranging
from 25 to 300 μM. The data were fit to the Sigmoidal Dose-Response model using XLfit
(IDBS).
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P. aeruginosa MetRS amino acid conservation (average) compared with homologs from different phyla.
MetRS

Similarity/Identity (%)

Gammaproteobacteria

73/61

Betaproteobacteria

58/48

Alphaproteobacteria

31/21

Delta-, Epsilonproteobacteria

37/24

Terrabacteria (not including Firmicutes)

35/23
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Firmicutes

40/25

Spirochaetales

33/22

Chlamydiae

36/25

FCB

43/28

Human mitochondria

28/18

Human cytosolic

29/18
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29

KM (μM)

1.93

kcat

(s−1)

tRNA

0.07

kcat/KM

(s−1
μM)
35

KM (μM)
37.2

kcat

(s−1)

Methionine

1.1

kcat/KM

(s−1
μM)
515

KM (μM)
24.2

kcat (s−1)

ATP

0.05

kcat/KM (s−1 μM)
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The kinetic parameter governing the interaction of MetRS with its substrates.
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Author Manuscript

Minimum inhibitory concentration of the hit compound against clinically important bacterial.
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a

Bacteria

Isopomiferin

E. coli (ATCC 25922)

128a

E. coli tolC (efflux mutant)

64

E. faecalis (ATCC 29212)

32

H. influenzae (ATCC 49766)

32

P. aeruginosa (ATCC 47085)

128

P. aeruginosa PAO200 (efflux mutant)

128

P. aeruginosa (hypersensitive)

16

S. aureus (ATCC 29213)

32

S. pneumoniae (ATCC 49619)

>128

The MIC (μg/ml) against each of the bacteria was determined in three separate sets of assays.
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